{"id":"https://openalex.org/W7215119767","doi":"https://doi.org/10.3389/fonc.2026.1956522","title":"Reshaping the definition of high-risk disease in the immune effector therapy era in multiple myeloma","display_name":"Reshaping the definition of high-risk disease in the immune effector therapy era in multiple myeloma","publication_year":2026,"publication_date":"2026-10-01","ids":{"openalex":"https://openalex.org/W7215119767","doi":"https://doi.org/10.3389/fonc.2026.1956522","pmid":"https://pubmed.ncbi.nlm.nih.gov/42889616","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13669832"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2026.1956522","doi":"https://doi.org/10.3389/fonc.2026.1956522","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1956522","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1956522/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1956522/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013935887","display_name":"Yoshito Nishimura","orcid":"https://orcid.org/0000-0003-0224-7501","observed_orcids":["https://orcid.org/0000-0003-0224-7501"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yoshito Nishimura","raw_affiliation_strings":["Division of Hematology, Department of Medicine, Mayo Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Department of Medicine, Mayo Clinic","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041468998","display_name":"Gunjan Gaur","orcid":"https://orcid.org/0009-0000-6064-0796","observed_orcids":["https://orcid.org/0009-0000-6064-0796"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gunjan Gaur","raw_affiliation_strings":["Division of Hematology, Department of Medicine, Mayo Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Department of Medicine, Mayo Clinic","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034020009","display_name":"Francesca Cottini","orcid":"https://orcid.org/0000-0001-8676-7840","observed_orcids":["https://orcid.org/0000-0001-8676-7840"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]},{"id":"https://openalex.org/I2802841970","display_name":"The Ohio State University Wexner Medical Center","ror":"https://ror.org/00c01js51","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Francesca Cottini","raw_affiliation_strings":["Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute","institution_ids":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076071872","display_name":"Saurabh Zanwar","orcid":"https://orcid.org/0000-0001-5074-8453","observed_orcids":["https://orcid.org/0000-0001-5074-8453"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Saurabh Zanwar","raw_affiliation_strings":["Division of Hematology, Department of Medicine, Mayo Clinic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Department of Medicine, Mayo Clinic","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5034020009","https://openalex.org/A5076071872"],"corresponding_institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I2799885155","https://openalex.org/I2802841970"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.56156156,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":null,"first_page":"1956522","last_page":"1956522"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9549999833106995},{"id":"https://openalex.org/keywords/high-risk-disease","display_name":"high-risk disease","score":0.8989999890327454},{"id":"https://openalex.org/keywords/chimeric-antigen-receptor-t-cells","display_name":"chimeric antigen receptor T cells","score":0.7269999980926514},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.9290000200271606},{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.8820000290870667},{"id":"https://openalex.org/keywords/gprc5d","display_name":"GPRC5D","score":0.9909999966621399},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.8600000143051147},{"id":"https://openalex.org/keywords/extramedullary-disease","display_name":"extramedullary disease","score":0.8090000152587891},{"id":"https://openalex.org/keywords/plasma-cell-leukemia","display_name":"plasma cell leukemia","score":0.9940000176429749},{"id":"https://openalex.org/keywords/beta2-microglobulin","display_name":"beta2-microglobulin","score":0.8669999837875366},{"id":"https://openalex.org/keywords/adverse-cytogenetics","display_name":"adverse cytogenetics","score":0.925000011920929},{"id":"https://openalex.org/keywords/ciltacabtagene-autoleucel","display_name":"ciltacabtagene autoleucel","score":0.9449999928474426},{"id":"https://openalex.org/keywords/fcrh5","display_name":"FcRH5","score":0.875},{"id":"https://openalex.org/keywords/cd70","display_name":"CD70","score":0.996999979019165},{"id":"https://openalex.org/keywords/antigen-escape","display_name":"antigen escape","score":0.8949999809265137},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5740000009536743}],"concepts":[{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.8015999794006348},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7583000063896179},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.6061000227928162},{"id":"https://openalex.org/C2780353925","wikidata":"https://www.wikidata.org/wiki/Q7201765","display_name":"Plasma cell leukemia","level":3,"score":0.5763000249862671},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5638999938964844},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.5343999862670898},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.507099986076355},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.45410001277923584},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.44190001487731934},{"id":"https://openalex.org/C51785407","wikidata":"https://www.wikidata.org/wiki/Q2627568","display_name":"Effector","level":2,"score":0.42419999837875366},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.421999990940094},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.420199990272522},{"id":"https://openalex.org/C2776396001","wikidata":"https://www.wikidata.org/wiki/Q250694","display_name":"Plasma cell","level":3,"score":0.4002000093460083},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3878999948501587},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3756999969482422},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.36419999599456787},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.3474000096321106},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.30489999055862427},{"id":"https://openalex.org/C194409129","wikidata":"https://www.wikidata.org/wiki/Q103824","display_name":"Hematology","level":2,"score":0.30410000681877136},{"id":"https://openalex.org/C83464605","wikidata":"https://www.wikidata.org/wiki/Q575296","display_name":"Antigen presentation","level":4,"score":0.28349998593330383},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.27950000762939453},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2759000062942505},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.27250000834465027},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.2671000063419342},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.25440001487731934}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fonc.2026.1956522","doi":"https://doi.org/10.3389/fonc.2026.1956522","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1956522","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1956522/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13669832","doi":null,"is_oa":true,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42889616/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13669832/pdf/fonc-16-1956522.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Oncol","raw_type":"Text"},{"id":"pmid:42889616","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42889616","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in oncology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:1191ab049cb24f6fb74b012e9d9c9242","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/1191ab049cb24f6fb74b012e9d9c9242","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, Vol 16 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fonc.2026.1956522","doi":"https://doi.org/10.3389/fonc.2026.1956522","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1956522","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1956522/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7215119767.pdf","grobid_xml":"https://content.openalex.org/works/W7215119767.grobid-xml"},"referenced_works_count":89,"referenced_works":["https://openalex.org/W2074995740","https://openalex.org/W2158285723","https://openalex.org/W2471662063","https://openalex.org/W2774700270","https://openalex.org/W2943335541","https://openalex.org/W3127802833","https://openalex.org/W3133229959","https://openalex.org/W4229446243","https://openalex.org/W4232756496","https://openalex.org/W4281653659","https://openalex.org/W4281714381","https://openalex.org/W4282033105","https://openalex.org/W4291926372","https://openalex.org/W4297519419","https://openalex.org/W4312072518","https://openalex.org/W4319812103","https://openalex.org/W4323656441","https://openalex.org/W4383645764","https://openalex.org/W4385644673","https://openalex.org/W4385698049","https://openalex.org/W4385839624","https://openalex.org/W4386324983","https://openalex.org/W4386698434","https://openalex.org/W4387266979","https://openalex.org/W4387373822","https://openalex.org/W4390706597","https://openalex.org/W4391052632","https://openalex.org/W4391845301","https://openalex.org/W4392215371","https://openalex.org/W4396213220","https://openalex.org/W4399068186","https://openalex.org/W4399236952","https://openalex.org/W4399391642","https://openalex.org/W4401744919","https://openalex.org/W4401877238","https://openalex.org/W4401877495","https://openalex.org/W4401878449","https://openalex.org/W4401942365","https://openalex.org/W4403568915","https://openalex.org/W4405017042","https://openalex.org/W4405043889","https://openalex.org/W4405051388","https://openalex.org/W4406080363","https://openalex.org/W4406848242","https://openalex.org/W4407673240","https://openalex.org/W4407762453","https://openalex.org/W4408392330","https://openalex.org/W4409147719","https://openalex.org/W4409256027","https://openalex.org/W4409257392","https://openalex.org/W4410338512","https://openalex.org/W4410484240","https://openalex.org/W4410795574","https://openalex.org/W4410997767","https://openalex.org/W4411141147","https://openalex.org/W4411248459","https://openalex.org/W4411635684","https://openalex.org/W4411707952","https://openalex.org/W4412116344","https://openalex.org/W4412123441","https://openalex.org/W4412836268","https://openalex.org/W4413348849","https://openalex.org/W4413785372","https://openalex.org/W4413788836","https://openalex.org/W4414084328","https://openalex.org/W4414302537","https://openalex.org/W4414303562","https://openalex.org/W4414398065","https://openalex.org/W4414616655","https://openalex.org/W4415258932","https://openalex.org/W4415396001","https://openalex.org/W4416265064","https://openalex.org/W4416780523","https://openalex.org/W4417002581","https://openalex.org/W4417010335","https://openalex.org/W4417017897","https://openalex.org/W4417098399","https://openalex.org/W4417156840","https://openalex.org/W7108481869","https://openalex.org/W7118918402","https://openalex.org/W7124829272","https://openalex.org/W7141266674","https://openalex.org/W7147533144","https://openalex.org/W7154506823","https://openalex.org/W7162578168","https://openalex.org/W7162673058","https://openalex.org/W7162767729","https://openalex.org/W7163376135","https://openalex.org/W7164695542"],"related_works":["https://openalex.org/W4417002045","https://openalex.org/W4394782733","https://openalex.org/W4310125415","https://openalex.org/W7162687330","https://openalex.org/W7108480234","https://openalex.org/W4411048515","https://openalex.org/W3111961404","https://openalex.org/W4414889250","https://openalex.org/W4417041717","https://openalex.org/W4405978026"],"abstract_inverted_index":{"Multiple":[0],"myeloma":[1],"(MM)":[2],"outcomes":[3],"have":[4],"improved":[5],"with":[6,20,156,169],"proteasome":[7],"inhibitors,":[8],"immunomodulatory":[9],"drugs,":[10],"anti-CD38":[11],"antibodies,":[12],"and":[13,28,38,55,89,104,122,140,152,159,165,175],"transplantation,":[14],"yet":[15],"a":[16],"subset":[17],"of":[18,61],"patients":[19],"high-risk":[21,87,109,147],"MM":[22],"(HRMM)":[23],"continues":[24],"to":[25,178,187],"relapse":[26],"early":[27],"die":[29],"prematurely.":[30],"Immune":[31],"effector":[32],"therapies":[33],"(IET)-B-cell":[34],"maturation":[35],"antigen":[36,50,180],"(BCMA)-":[37],"G":[39],"protein-coupled":[40],"receptor":[41,51],"class":[42],"C":[43],"group":[44],"5":[45],"member":[46],"D":[47],"(GPRC5D)-directed":[48],"chimeric":[49],"T":[52],"cells":[53],"(CAR-T)":[54],"bispecific":[56,142],"antibodies-have":[57],"transformed":[58],"the":[59,80],"treatment":[60],"relapsed/refractory":[62],"MM.":[63],"However,":[64],"their":[65],"benefit":[66],"in":[67,79,129,146,192],"HRMM":[68,76],"remains":[69],"incompletely":[70],"defined.":[71],"This":[72],"review":[73],"describes":[74],"how":[75],"is":[77],"defined":[78],"IET-era":[81],"distinguishing":[82],"baseline":[83],"biological/genomic":[84],"risk,":[85],"clinical":[86],"phenotypes,":[88],"IET-specific":[90],"adverse":[91,102],"predictors.":[92],"The":[93],"International":[94],"Myeloma":[95,97],"Society/International":[96],"Working":[98],"Group":[99],"consensus":[100],"integrates":[101],"cytogenetics":[103],"beta-2":[105],"microglobulin,":[106],"whereas":[107,150],"functional":[108],"disease,":[110],"extramedullary":[111],"disease":[112,128,190],"(EMD),":[113],"plasma":[114],"cell":[115],"leukemia":[116],"(PCL),":[117],"high":[118],"tumor":[119],"burden,":[120],"inflammation,":[121],"prior":[123],"BCMA":[124],"exposure":[125],"identify":[126],"aggressive":[127],"relapsed":[130],"patients.":[131],"Across":[132],"pivotal":[133],"trials,":[134],"CAR-T":[135],"therapy,":[136],"particularly":[137],"ciltacabtagene":[138],"autoleucel,":[139],"selected":[141],"antibodies":[143],"retain":[144],"activity":[145],"cytogenetic":[148],"subgroups,":[149],"EMD":[151],"PCL":[153],"remain":[154],"associated":[155],"inferior":[157],"responses":[158],"short":[160],"progression-free":[161],"survival.":[162],"Emerging":[163],"dual-antigen":[164],"trispecific":[166],"engagers,":[167],"along":[168],"novel":[170],"targets":[171],"such":[172],"as":[173],"FcRH5":[174],"CD70,":[176],"aim":[177],"overcome":[179],"escape.":[181],"Prospective,":[182],"biology-informed":[183],"studies":[184],"are":[185],"needed":[186],"achieve":[188],"durable":[189],"control":[191],"HRMM.":[193]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-02T00:00:00"}